Nucleotide excision repair and anti-cancer chemotherapy |
| |
Authors: | Eddie Reed |
| |
Affiliation: | (1) Division of Clinical Sciences, National Cancer Institute, Building 10, Room 12N226, Bethesda, MD, 20892, U.S.A. E-mail |
| |
Abstract: | DNA repair is an important effector of anti-cancer drug resistance. In recent years, it has become apparent that DNA repair is an extremely complex process. Processes within DNA repair that may contribute to one or more drug resistance phenotypes include; O-6-alkyltransferase activity, base excision repair, mismatch repair, nucleotide excision repair, and gene specific repair. Clearly, several of these processes may show increased activity within any single cell, or tumor, at any one time. This review attempts to touch briefly upon the question of the distinctions between each of these specific pathways; and then seeks to expand on nucleotide excision repair as a possible effector of cellular and clinical resistance to platinum-based anticancer therapy. This revised version was published online in August 2006 with corrections to the Cover Date. |
| |
Keywords: | DNA adduct ERCC1 nucleotide excision repair ovarian cancer platinum compounds |
本文献已被 SpringerLink 等数据库收录! |
|